Rodríguez CFE

Language: Spanish
References: 10
Page: 177-181
PDF size: 57.83 Kb.

ABSTRACT

The decision to treat, or not treat, uncomplicated mild hypertension should be based on a formal estimate of absolute cardiovascular risk and not on an arbitrary blood pressure threshold. The decision to initiate pharmacologic treatment requires consideration of the degree of blood pressure elevation, the presence of target organ damage, and the presence of clinical cardiovascular disease or other risk factors. Special considerations include demographic characteristics, concomitant diseases that may be beneficially or adversely affected by the antihypertensive agent chosen, quality of life, cost, and use of other drugs that may lead to drug interactions. Diuretics, β-blockers or ACE inhibitors may be used as first-step drug therapies for the treatment of uncomplicated hypertension. Genetic factors may contribute to interindividual differences in responses to antihypertensive drug therapy. Knowledge of polymorphic variation in these genes will help to predict individual patients’ blood pressure responses to antihypertensive drug therapy and may also provide new insights into molecular mechanisms responsible for elevation of blood pressure.

REFERENCES

1. Whelton PK, He J: Blood pressure reduction. En: Hennekens CH, Buring JE, Manson JE, Ridker PM, eds. Clinical trials in cardiovascular disease: a companion to Braunwald’s heart disease. Philadelphia. Saunders, 1999.

2. He J, Whelton PK: Selection of initial antihypertensive drug therapy. Lancet 2000; 356: 1942-3.

3. Bauer JH, Reams GP: Antihypertensive drugs. En: Brenner BM, ed. The Kidney. 6th Ed. Philadelphia. Saunders, 2000.

4. Ramsay LE, Wallis EJ, Yeo WW, Jackson PR: The rationale for differing national recommendations for the treatment of hypertension. Am J Hypertens 1998; 11: 79S-88S.

5. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46.

6. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, Ramírez EA, Henderson WG: Single drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-921.

7. Agodoa LY, Appel L, Bakris GL, et al, for the African American Study of Kidney Disease and Hypertension (AASK) Study Group: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomised controlled trial. JAMA 2001; 285: 2719-2728.

8. Blood Pressure Lowering Treatment Trialists’ Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955-64.

9. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, Furberg CD: Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 356: 1949-54.

10. Turner ST, Schwartz GL, Chapman AB, Hall WD, Boerwinkle E: Antihypertensive pharmacogenetics: getting the right drug into the right patient. J Hypertens 2001; 19: 1-11.